相关实验视频

Updated: Jul 15, 2026

In Vitro Synthesis of Modified mRNA for Induction of Protein Expression in Human Cells

In Vitro Synthesis of Modified mRNA for Induction of Protein Expression in Human Cells

Published on: November 13, 2014

为临床级RNA疫苗制造生产等离子体DNA模板

Ram Shankar¹, Marco Schmeer¹, Martin Schleef²

¹PlasmidFactory GmbH, Bielefeld, Germany.

Methods in molecular biology (Clifton, N.J.)

|May 30, 2024

概括

现在可以使用大规模的等离子体DNA生产工艺制造mRNA疫苗. 这一进步支持临床试验,并解决了全球急需的基于核酸的疗法.

科学领域:

生物技术是生物技术.
疫苗开发疫苗开发
监管科学监管科学

背景情况:

建立了大规模的等离子体DNA生产,以获得高质量的原料.
mRNA疫苗需要高质量的等离子体DNA作为关键原料.
世界卫生组织 (WHO) 发布了关于疫苗质量,安全性和有效性的新监管准则.

研究的目的:

为了突出一个大规模的塑体DNA制造工艺的建立.
将这一过程置于疫苗开发和监管领域的最新进展的背景下.
为满足日益增长的基于核酸的疫苗和疗法的需求.

主要方法:

开发和实施可扩展的等离子体DNA生产过程.
遵守高质量的等离子体DNA的良好制造实践 (GMP).
与新发布的世卫组织关于疫苗成分的监管指南的调整.

主要成果:

成功建立了高质量的,大规模的等离子体DNA制造工艺.
等离子体DNA已准备好作为临床试验中mRNA疫苗生产的起始材料.
加强全球对大规模基于核酸的疫苗和治疗制造的准备.

结论:

已建立的等离子体DNA生产过程对于推进mRNA疫苗开发和临床试验至关重要.
改善原材料供应链的协调对于生物制造至关重要,特别是在紧急情况下.
科学,监管和制造业的进步使社区能够更好地应对紧急的生产需求.

关键词:

高质量等级的高质量等级.一个流行病的流行病.疫苗疫苗是一种疫苗.它们是mRNARNA.塑体DNA DNA 的意思.

更多相关视频

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Published on: June 9, 2022

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

相关概念视频

Vaccine Production

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...